Confer Health is a technology company.
Confer Health has raised $10.0M across 1 funding round.
Confer Health has raised $10.0M in total across 1 funding round.
Confer Health is a Boston-based biotechnology company founded in 2015 that develops affordable at-home health testing kits using a proprietary diagnostic platform for clinical-grade sensitivity.[1][2][3][5] It builds products that deliver personalized, actionable health insights by adapting to users' unique biology, matching the accuracy of doctors' tests while prioritizing ease of use and people-centric design.[2] The company serves consumers seeking proactive healthcare at home, solving the problem of inaccessible, lab-like diagnostics by creating technology from scratch rather than adapting hospital tools.[1][2]
Confer Health originated from a personal challenge during founder Mounir Koussa's PhD at Harvard Medical School, where he researched inner ear mechanics at the nanoscale.[1] A drugstore conversation with a close friend frustrated by unreliable at-home pregnancy tests sparked the idea to adapt his lab technology—capable of detecting single molecules—for consumer use, leading to a diagnostic platform published in *Nature Methods*.[1] After his dissertation, Koussa founded Confer in 2015 alongside co-founders Joshua Forman and Zhi-Yang Tsun, assembling a team of scientists and engineers from Harvard and MIT to build a new platform designed for home use from the ground up.[1][2][3]
Confer Health rides the wave of consumerized diagnostics and at-home health tech, accelerated by post-pandemic demand for accessible testing amid rising chronic disease management needs.[1][2] Its timing aligns with advances in nanotechnology and biotech enabling lab precision in consumer devices, countering market forces like healthcare access gaps and high lab costs.[1][5] By democratizing clinical-grade tools, Confer influences the ecosystem toward proactive, personalized medicine, potentially reducing reliance on in-person visits and fostering competition in direct-to-consumer biotech.[2]
Confer Health's momentum stems from its science-first foundation, positioning it to expand beyond initial tests into broader at-home monitoring as biotech miniaturization and AI personalization trends accelerate.[1][2] Regulatory approvals for expanded kits and partnerships with telehealth could drive growth, evolving its role from niche innovator to key player in decentralized healthcare. Watch for scaling challenges in manufacturing and distribution, but its origin in real-world need suggests sustained impact in making precision health ubiquitous.[1][5]
Confer Health has raised $10.0M in total across 1 funding round.
Confer Health's investors include Ecliptic Capital, Firework Ventures, Social Capital.
Confer Health has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Venture Round in April 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2018 | $10.0M Venture Round | Ecliptic Capital, Firework Ventures, Social Capital |